Showing results (91-100 of 301) with videos related to
Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal MalignanciesKhaldoun Almhanna, Thea Kalebic, Cristina Cruz, et al.American Journal of Clinical Oncology|December 15, 2004
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumorsA David McCollum, Matthew H Kulke, David P Ryan, et al.Cancer|January 22, 2008
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinomaPaul Wheatley-Price, Kofi Asomaning, Amy Reid, et al.JAMA Network Open|April 13, 2019
Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal CancerAnn C Raldow, Aileen B Chen, Marcia Russell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumorsMatthew H Kulke, Keith Stuart, Peter C Enzinger, et al.Journal of Vascular and Interventional Radiology : JVIR|March 31, 2009
Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapyWalter J Zawacki, T Gregory Walker, Emily DeVasher, et al.The Oncologist|April 12, 2014
Caring for one of our ownLidia Schapira, Lawrence S Blaszkowsky, Barbara J Cashavelly, et al.Cancer Discovery|October 11, 2011
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine networkHaoqiang Ying, Kutlu G Elpek, Anant Vinjamoori, et al.International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and olderDanielle N Margalit, Harvey J Mamon, Marek Ancukiewicz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumorsJeffrey G Supko, Joseph P Eder, David P Ryan, et al.Pageof 31